menu
    • menu
    [{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enliven Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enliven Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enliven Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Commodore Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Enliven Therapeutics \/ Commodore Capital","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Commodore Capital"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Imara","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Merger","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enliven Therapeutics \/ Imara","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Imara"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enliven Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Fairmount Funds Management LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Enliven Therapeutics \/ Fairmount Funds Management LLC","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Fairmount Funds Management LLC"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Imara","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Merger","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enliven Therapeutics \/ Imara","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Imara"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Enliven Therapeutics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ELVN-002","moa":"EGFR exon 20","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Enliven Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ELVN-002","moa":"EGFR exon 20","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Enliven Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Enliven Therapeutics

    Menu

    Enliven Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Enliven Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Enliven Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ELVN-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Jefferies

                            Deal Size : $200.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Enliven Sets Pricing for Public Offering of Stock and Pre-Funded Warrants

                            Details : The proceeds will fund ongoing research and development activities, including a planned Phase 3 clinical trial of ELVN-001, a potent, highly selective, small molecule kinase inhibitor.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 13, 2025

                            Lead Product(s) : ELVN-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Jefferies

                            Deal Size : $200.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Enliven Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Enliven Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ELVN-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participant...

                            Details : ELVN-001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 22, 2025

                            Lead Product(s) : ELVN-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Enliven Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Enliven Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ELVN-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Enliven Therapeutics Reports Positive Data on ELVN-001 in Chronic Myeloid Leukemia

                            Details : ELVN-001 is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 28, 2024

                            Lead Product(s) : ELVN-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Enliven Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Enliven Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ELVN-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Enliven Therapeutics Reports Positive Phase 1 Data Of ELVN-001 in Chronic Myeloid Leukemia

                            Details : ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for CML.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 11, 2024

                            Lead Product(s) : ELVN-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Enliven Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Enliven Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ELVN-002,Trastuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

                            Details : ELVN-002 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 25, 2024

                            Lead Product(s) : ELVN-002,Trastuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Enliven Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Enliven Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ELVN-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Commodore Capital

                            Deal Size : $90.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Enliven Therapeutics Announces $90 Million Financing and Pipeline Updates

                            Details : Enliven intends to use proceeds to fund research & development of clinical-stage product candidates, including ELVN-001, a selective small molecule kinase inhibitor targeting the BCR-ABL gene fusion.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            March 19, 2024

                            Lead Product(s) : ELVN-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Commodore Capital

                            Deal Size : $90.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Enliven Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Enliven Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ELVN-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Fairmount Funds Management LLC

                            Deal Size : $165.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million

                            Details : ELVN-001 is a potent, highly selective kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            February 23, 2023

                            Lead Product(s) : ELVN-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Fairmount Funds Management LLC

                            Deal Size : $165.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Enliven Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Enliven Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ELVN-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Imara

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million

                            Details : The combined company will focus on advancing Enliven’s pipeline of precision oncology product candidates. ELVN-001 is a highly selective small molecule BCR-ABL inhibitor, being developed for the treatment of chronic myeloid leukemia (CML).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            February 23, 2023

                            Lead Product(s) : ELVN-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Imara

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Enliven Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Enliven Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ELVN-002

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

                            Details : ELVN-002 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 14, 2022

                            Lead Product(s) : ELVN-002

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Enliven Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Enliven Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ELVN-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Imara

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Enliven Therapeutics and Imara Announce Merger Agreement

                            Details : The combined company will focus on advancing Enliven’s pipeline of precision oncology product candidates. ELVN-001 is a highly selective small molecule BCR-ABL inhibitor, being developed for the treatment of chronic myeloid leukemia (CML).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 13, 2022

                            Lead Product(s) : ELVN-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Imara

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.